Biopharma markets are never dull. The winners win big and the companies that lose are harshly penalized. Now the dust has settled, here's the final tally from Evaluate Pharma's review of biopharma markets in 2016.
It's not all doom and gloom for CAR-T immunotherapy. One week after the death of two patients in a trial by Juno Therapeutics, early-stage competitor bluebird bio has released positive interim results for its Phase 1 trial.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
A Juno and Celgene collaboration will focus on T cell therapeutics for cancer, one in eight people is pre-diabetic but a new study shows a willingness to change behavior if made aware of their risk.